These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1856149)

  • 1. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections.
    Beaucaire G; Leroy O; Beuscart C; Karp P; Chidiac C; Caillaux M
    J Antimicrob Chemother; 1991 May; 27 Suppl C():91-103. PubMed ID: 1856149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of once-daily amikacin in combination with ceftazidime in critically ill adults with severe gram-negative infections.
    Fayed DF; Dahmash NS; al-Zeer AH; Shibl AM; Huraib SO; Abu-Aisha H
    J Chemother; 1996 Dec; 8(6):457-64. PubMed ID: 8981187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
    Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F;
    Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single daily dose amikacin in paediatric patients with severe gram-negative infections.
    Trujillo H; Robledo J; Robledo C; Espinal D; Garces G; Mejia J; Restrepo C; Restrepo F; Mejia de Rodriguez GI; Tamayo de Guitierrez MC
    J Antimicrob Chemother; 1991 May; 27 Suppl C():141-7. PubMed ID: 1856143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.
    Rolston KV; Berkey P; Bodey GP; Anaissie EJ; Khardori NM; Joshi JH; Keating MJ; Holmes FA; Cabanillas FF; Elting L
    Arch Intern Med; 1992 Feb; 152(2):283-91. PubMed ID: 1739355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection.
    Colardyn F
    J Chemother; 1995 Jun; 7 Suppl 2():129-35. PubMed ID: 8622101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. Scandinavian Amikacin Once Daily Study Group.
    Maller R; Ahrne H; Eilard T; Eriksson I; Lausen I
    J Antimicrob Chemother; 1991 May; 27 Suppl C():121-8. PubMed ID: 1856141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
    Charnas R; Lüthi AR; Ruch W
    Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of amikacin given once versus twice daily in serious infections.
    Maller R; Isaksson B; Nilsson L; Sörén L
    J Antimicrob Chemother; 1988 Jul; 22(1):75-9. PubMed ID: 3170393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Ann Intern Med; 1993 Oct; 119(7 Pt 1):584-93. PubMed ID: 8363169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens.
    Marik PE; Havlik I; Monteagudo FS; Lipman J
    J Antimicrob Chemother; 1991 May; 27 Suppl C():81-9. PubMed ID: 1856148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective randomized study of once-daily versus twice-daily amikacin regimens in patients with systemic infections.
    Karachalios GN; Houpas P; Tziviskou E; Papalimneou V; Georgiou A; Karachaliou I; Halkiadaki D
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):561-4. PubMed ID: 9799062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.
    Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA
    Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebulized Versus IV Amikacin as Adjunctive Antibiotic for Hospital and Ventilator-Acquired Pneumonia Postcardiac Surgeries: A Randomized Controlled Trial.
    Hassan NA; Awdallah FF; Abbassi MM; Sabry NA
    Crit Care Med; 2018 Jan; 46(1):45-52. PubMed ID: 28857848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
    Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
    Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and pharmacokinetic study of a single daily dose of amikacin in paediatric patients with severe gram-negative infections.
    Kafetzis DA; Sianidou L; Vlachos E; Davros J; Baïramis T; Papandreou Y; Paraskaki E; Scouroliakou M; Hadzis A; Papadatos J
    J Antimicrob Chemother; 1991 May; 27 Suppl C():105-12. PubMed ID: 1906861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.
    De Jongh CA; Joshi JH; Thompson BW; Newman KA; Finley RS; Moody MR; Salvatore PC; Tenney JH; Drusano GL; Schimpff SC
    Am J Med; 1986 May; 80(5C):101-11. PubMed ID: 3521269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections.
    Giamarellou H; Yiallouros K; Petrikkos G; Moschovakis E; Vavouraki E; Voutsinas D; Sfikakis P
    J Antimicrob Chemother; 1991 May; 27 Suppl C():73-9. PubMed ID: 1906864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once daily dosing of aminoglycoside: one step forward.
    Pechère JC; Craig WA; Meunier F
    J Antimicrob Chemother; 1991 May; 27 Suppl C():149-52. PubMed ID: 1856144
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.